AC
VRTX icon

Allstate Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

Allstate Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.61M Buy
21,523
+2,428
+13% +$1.13M 0.1% 114
2025
Q4 		$8.66M Buy
19,095
+9,803
+105% +$4.23M 0.12% 113
2025
Q3 		$3.64M Buy
+9,292
New +$3.88M 0.08% 132
2025
Q2 		– Sell
-7,487
Closed -$3.63M – 550
2025
Q1 		$3.63M Sell
7,487
-128
-2% -$59.6K 0.11% 119
2024
Q4 		$3.07M Buy
+7,615
New +$3.53M 0.09% 125
2024
Q3 		– Sell
-906
Closed -$425K – 223
2024
Q2 		$425K Sell
906
-19
-2% -$8.25K 0.03% 136
2024
Q1 		$387K Sell
925
-6
-0.6% -$2.54K 0.03% 141
2023
Q4 		$379K Sell
931
-58
-6% -$21.4K 0.03% 132
2023
Q3 		$344K Hold
989
– – 0.02% 140
2023
Q2 		$348K Buy
989
+6
+0.6% +$2.02K 0.02% 144
2023
Q1 		$310K Sell
983
-11,653
-92% -$3.5M 0.02% 147
2022
Q4 		$3.65M Hold
12,636
– – 0.11% 128
2022
Q3 		$3.66M Hold
12,636
– – 0.11% 118
2022
Q2 		$3.56M Sell
12,636
-6,238
-33% -$1.67M 0.11% 120
2022
Q1 		$4.93M Sell
18,874
-208
-1% -$49.4K 0.13% 114
2021
Q4 		$4.19M Buy
19,082
+12,315
+182% +$2.39M 0.08% 194
2021
Q3 		$1.23M Sell
6,767
-387
-5% -$75.6K 0.05% 243
2021
Q2 		$1.44M Sell
7,154
-1,392
-16% -$291K 0.05% 211
2021
Q1 		$1.84M Buy
8,546
+2,111
+33% +$464K 0.06% 174
2020
Q4 		$1.52M Sell
6,435
-1,368
-18% -$314K 0.05% 192
2020
Q3 		$2.12M Sell
7,803
-1,715
-18% -$473K 0.07% 88
2020
Q2 		$2.76M Buy
9,518
+257
+3% +$69.7K 0.09% 81
2020
Q1 		$2.2M Sell
9,261
-21,700
-70% -$4.98M 0.09% 97
2019
Q4 		$6.78M Buy
30,961
+174
+0.6% +$35.2K 0.12% 94
2019
Q3 		$5.22M Buy
30,787
+1,961
+7% +$347K 0.09% 129
2019
Q2 		$5.29M Buy
28,826
+3,863
+15% +$675K 0.09% 119
2019
Q1 		$4.59M Hold
24,963
– – 0.12% 116
2018
Q4 		$4.14M Buy
+24,963
New +$4.33M 0.14% 113

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Allstate Corporation's VRTX Position: Q1 2026 in Review

Allstate Corporation increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $1.13M and bringing the position to 21,523 shares worth $9.61M. The position accounts for 0.1% of the portfolio, ranked #114.

Allstate Corporation first reported a position in VRTX in Q4 2018 and has held it in 28 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Allstate Corporation held 21,523 shares of Vertex Pharmaceuticals worth $9.61M as of Q1 2026.
  • Allstate Corporation bought 2,428 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
  • Vertex Pharmaceuticals made up 0.1% of Allstate Corporation's portfolio in Q1 2026, its #114 holding.
  • Allstate Corporation first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Allstate Corporation's 13F filing for Q1 2026, filed 11 May 2026.